TORONTO--(BUSINESS WIRE)--Axela Inc. has launched nine plate based tumor marker assays. Available in high performance ELISA format they have been designed for stand alone use or to simplify the transition to automated dotLab assays. Used in conjunction with Axela’s panelPlus™ biomarker menu (available for the dotLab® system this summer) this unique approach has the potential to significantly transform the speed with which putative biomarkers can be validated. The following RUO (Research Use Only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP); carcinoembroyonic antigen (CEA); CA125; CA15-3; CA 19-9; PSA; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin (free beta-hCG) and beta-2 Microglobulin (B2MG).
